Amicus Therapeutics Inc is a biotechnology company. It is focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is expanding a pipeline of medicines for rare metabolic diseases, including an industry- leading rare disease gene therapy portfolio.
| Website: | www.amicusrx.com |
| Email: | ir@amicusrx.com |
| Main Phone: | +1 609 662-2000 |
| Address: | 1 Cedar Brook Drive |
| State: | NJ |
| City / Town: | Cranbury |
| Country: | US |
| Postal Code: | 08512 |
| Exchange: | NSD |
| CEO: | John F. Crowley |
| Employees: | 584 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Stocks were trading higher on Tuesday as all the major indices posted significant gains, with the Nasdaq leading the charge. Among the day’s big gainers were growth companies and biotechs,
Shares in Amicus Therapeutics (FOLD) spiked on Tuesday following the news that its lead therapy, climbing over 20 percent after reporting success in Phase III trials of migalastat HCL in
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
After missing earlier this month on achieving a statistically significant response in a phase 3 study with partner GlaxoSmithKline (GSK) for migalastat HCl against Fabry disease that chopped their
Initial Jobless Claims were higher than expected in the latest week at 428,000. Remember that the Recessionary Threshold is 350,000. The Chicago PMI rose to a stronger than expected reading of
Amicus Therapeutics Inc is a biotechnology company. It is focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is expanding a pipeline of medicines for rare metabolic diseases, including an industry- leading rare disease gene therapy portfolio.
| Website: | www.amicusrx.com |
| Email: | ir@amicusrx.com |
| Main Phone: | +1 609 662-2000 |
| Address: | 1 Cedar Brook Drive |
| State: | NJ |
| City / Town: | Cranbury |
| Country: | US |
| Postal Code: | 08512 |
| Exchange: | NSD |
| CEO: | John F. Crowley |
| Employees: | 584 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Stocks were trading higher on Tuesday as all the major indices posted significant gains, with the Nasdaq leading the charge. Among the day’s big gainers were growth companies and biotechs,
Shares in Amicus Therapeutics (FOLD) spiked on Tuesday following the news that its lead therapy, climbing over 20 percent after reporting success in Phase III trials of migalastat HCL in
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
After missing earlier this month on achieving a statistically significant response in a phase 3 study with partner GlaxoSmithKline (GSK) for migalastat HCl against Fabry disease that chopped their
Initial Jobless Claims were higher than expected in the latest week at 428,000. Remember that the Recessionary Threshold is 350,000. The Chicago PMI rose to a stronger than expected reading of
| Last Price 13.48 | Change $ -1.12 | Change % -7.67 | Tick N/A |
| Bid 13.30 | Bid Size 100.00 | Ask 14.97 | Ask Size 500.00 |
| Open 14.31 | High 14.35 | Low 13.41 | Prev Close 14.60 |
| Last Trade | Volume 2.3 mi | 52 Wk Hi 16.13 | 52 Wk Low 6.25 |
| Market Cap 3.5 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 258,787,743.00 | EPS (TTM) -1.14 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 22 | 110 |
| Number of Buys | 13 | 61 |
| Number of Sells | 9 | 49 |
| Net Activity | -78433 | 2199222 |
| Last 10 Buys | Shares |
|---|---|
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Ellen S. Rosenberg | 1,000 |
| Margaret G. McGlynn | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Hung Do | 1,000 |
| Hung Do | 1,000 |
| Margaret G. McGlynn | 1,000 |
| Jay Barth | 1,000 |
| Hung Do | 1,000 |
| Michael G. Raab | 1,000 |
| Jay Barth | 1,000 |
| Kurt J. Andrews | 1,000 |
| William D. Baird | 1,000 |
| Jay Barth | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 22 | 22 | 22 | 22 |
| Low Target Price Estimate | 18.5 | 18.5 | 18.5 | 18.5 |
| Mean Target Price Estimate | 20.08 | 20.08 | 20.08 | 20.08 |
| Standard Deviation | 1.56 | 1.56 | 1.56 | 1.56 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 05/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 8-K | Report of unscheduled material events or corporate changes. | 21 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait